

Publikationsliste Abteilung für Innere Medizin, Hämatologie, Onkologie und Palliativmedizin, Ev. Stift St. Martin, Gemeinschaftsklinikum Mittelrhein seit 10/2017 (Stand 01/2024)

Originalarbeiten

1. Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf T, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, **Niemann D**, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Validation of the revised 2022 european leukemianet (ELN) risk stratification in adult patients with acute myeloid leucemia.
(in preparation)
2. Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, **Niemann D**, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Serve H, Ehninger G, Mayer J, and Bornhäuser M. Single versus double induction with “7+3” containing 60 versus 90 mg daunorubicin for newly diagnosed AML. Results from the randomized controlled SAL-DaunoDouble trial.
(in preparation)
3. Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Crysandt M, Görner M, Trappe RU, Kayser S, Krause S, Schliemann C, Gaska T, Kaufmann M, **Niemann D**, Herrmann M, Schaich M, Hoellein A, **Chemnitz J**, Kieser M, Platzbecker U, Müller-Tidow C, Schlenk RF. GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed AML.
Haematologica (submitted)
4. Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch JH, Krause S, Sauer T, Hanoun M, Reinhardt HC, Kraus S, Kaufmann M, Hänel M, Fransecky L, Burchert A, Neubauer A, Crysandt M, Jost E, **Niemann D**, Schäfer-Eckart K, Held G, Kaiser U, Wass M, Schaich M, Müller-Tidow C, Platzbecker U, Baldus CD, Bornhäuser M, Röllig C, Serve H, Steffen B for the Study Alliance Leukemia (SAL). Impact of BMI on patient outcome in acute myeloid leukemia patients receiving intensive induction therapy: a real-world registry experience
Br J Cancer 2023 Oct; 129(7): 1126-1133 Impact factor 9.000
5. Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf T, Fransecky L, Kraus S, Einsele H, **Niemann D**, Neubauer A, Kullmer J, Seggewiß-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H,

- Röllig C for the Study Alliance Leukemia (SAL). Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit. Real world data from the german SAL-AML registry
J Cancer Res Clin Oncol 2023 Jul;149(8): 4611-4621..... **Impact factor: 4,322**
6. Hamacher R, Liu X, Schuler M, Hentschel L, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Kunitz A, Grünwald V. A post hoc analysis of the EPAZ trial: the role of geriatric variables in elderly soft tissue sarcoma (STS) patients on toxicity and outcome.
Eur J Cancer 2023 Mar;181: 145-154..... **Impact factor 10.002**
 7. Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt C, Aguiar E, Schäfer-Eckart K, Miguel Bergua J, Steffen B, Bernal T, Krause SW, Rianza R, Schliemann C, Kaufmann M, Hänel M, Jost E, Crysandt M, Fransecky L, Kraus S, Einsele H, **Niemann D**, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein S, Schmid C, Schaich M, Schmidt-Hieber M, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Montesinos P, Röllig C, Schlenk RF. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Haematologica 2023 Jan 1; 108(1): 34 – 41.....**Impact factor: 11,047**
 8. Werner R, Lohr B, Lodemann P, **Chemnitz JM**, Woehrl JC. Autoimmune basal ganglia encephalitis with hemolytic anemia
Ann Hematol 2022 Aug;101(8):1857-1858..... **Impact factor: 3,673**
 9. Ruhnke L, Röllig C, Hanoun M, Steffen B, Krause SW, Scholl S, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Schliemann C, Hänel M, Schaich M, Neubauer A, **Niemann D**, Seggewiß-Bernhardt R, Meinhardt A, Görner M, Schmidt-Hieber M, Kullmer J, Kramer M, Middeke JM, Stölzel F, Müller-Tidow C, Baldus CD, Platzbecker U, Bornhäuser M, Serve H, Thiede C. Prevalence and prognostic value of *IDH1* and *IDH2* mutations in patients with AML: prospective real-world data from the Study Alliance Leukemia AML registry (submitted)
 10. Lohr B, **Niemann D**, Verheyen J. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient
Clin Infect Dis. 2021 Dec 6;73(11):2144-2145..... **Impact factor: 9,117**
 11. Kayser S, Schlenk RF, Lebon D, Carre M, Götze KS, Stölzel F, Berceanu A, Schäfer-Eckart K, Peterlin P, Hicheri Y, Rahmé R, Raffoux E, Chermat F, Krause SW, Aulitzky WE, Rigau deau S, Noppeney R, Berthon C, Görner M, Jost E, Carassou P, Keller U, Orvain C, Braun T, Saillard C, Arar A, Kunzmann V, Wemeau M, de Wit M, **Niemann D**, Bonmati C, Schwänen C, Abraham J, Aljjakli A, Haiat S, Krämer A, Reichle A, Gnadler M, Willekens C, Spiekermann K, Hiddemann W, Müller-Tidow C, Thiede C, Röllig C, Serve H, Bornhäuser M, Baldus CD, Lengfelder E, Fenaux P, Platzbecker U and Adès L. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Haematologica 2021 Dec 1;106(12): 3100 - 3106..... **Impact factor: 11.047**

12. Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, Rank A, Behringer D, Teichmann L, Görner M, Trappe RU, Röllig C, Krause S, Hanoun M, Hopfer O, Held G, Buske S, Fransecky L, Kayser S, Schliemann C, Schaefer-Eckart K, Al-Fareh Y, Schubert J, Geer T, Kaufmann M, Brecht A, **Niemann D**, Kieser M, Bornhäuser M, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C and Schlenk RF. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
Trials 2021 Nov 3;22(1): 765..... **Impact factor: 2,049**

13. Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeeck M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, **Chemnitz J**, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Henning L, Kobbe G, Haas R, Alakel N, von Bonin M, Sockel K, Hanoun M, Platzbecker U, Holderried T, Morgner A, Heuser M, Sauer T, Götze K, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T and Middeke JM. Real-world experience of CPX-351 as first-line approach for patients with acute myeloid leukemia
Blood Cancer J. 2021 Oct 4;11(10)..... **Impact factor: 8,023**

14. Kiani A, Rösch R, Wendtner CM, Kullmann F, Kubin T, Lanznaster J, Wilhelm M, Schaich M, Müller-Naendrup C, Illerhaus G, Hartmann F, Hebart H, Seggewiss-Bernhardt R, Bentz M, Späth-Schwalbe E, Reimer P, Kaiser U, Kapp M, Graeven U, **Chemnitz JM**, Baesecke J, Lambertz H, Naumann R. Pre-infection laboratory parameters may predict COVID-19 severity in tumor patients.
Cancer Med 2021 Jul;10(13):4424-4436..... **Impact factor: 3.362**

15. Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, **Chemnitz J**, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Blood Adv. 2021 Jul 13;5(13):2707-2716 **Impact factor: 4.910**

16. Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause SW, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, **Niemann D**, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood 2020 Aug 13;136(7):823-830..... **Impact factor: 16,601**

17. Hentschel L, Richter S, Kopp HG, Kasper B, Kunitz A, Grünwald V, Kessler T, **Chemnitz JM**, Pelzer U, Schuler US, Freitag J, Schilling A, Hornemann B, Arndt K, Bornhäuser M, Schuler M. Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG).
BMJ Open 2020 Aug 27;10(8):e035546..... **Impact factor: 2,376**

18. Grünwald V, Karch A, Schuler M, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner LH, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Zimmermann S, Kunitz A. Randomized comparison of pazopanib and doxorubicin as first line treatment in metastatic soft tissue sarcoma patients ≥ 60 years of age - results of an German intergroup study
J Clin Oncol. 2020 Oct 20;38(30):3555-3564..... **Impact factor: 17.157**

19. Hartmann JT, Kopp HG, Gruenwald V, Piperno-Neumann S, Kunitz A, Hofheinz R, Mueller L, Geissler M, Horger M, Fix P, **Chemnitz J**, Neise M, Eckert R, Hann von Weyhern C, Bauer S, Mayer F. Randomized Phase II Trial of Trofosamide vs. Doxorubicin in Elderly Patients with untreated metastatic Soft Tissue Sarcoma.
Eur J Cancer. 2020 Jan;124:152-160.....**Impact factor: 6,680**

20. Ram R, Scheid C, Amit O, **Chemnitz JM**, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U. Sequential Therapy for Patients with Primary Refractory AML – A retrospective analysis of the German and Israeli Experience.
Haematologica 2019 Sep;104(9):1798-1803..... **Impact factor: 9,090**

- (21.) Hofheinz R, Wenz F, Post S, ... , **Fritz E**, ... , Hochhaus, A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Lancet Oncol. 2012 Jun;13(6):579-88. **Impact factor: 35.386**

Abstracts

1. Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Wass M, Fransecky L, **Chemnitz J**, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Kobbe G, Alakel N, von Bonin M, Sockel K, Hanoun M, Platzbecker U, Holderried T, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T and Middeke JM. Real-world experience with CPX-351 for patients with acute myeloid leukemia – long-term follow-up with focus on younger patients (<60 years old) and allogeneic stem cell transplantation.
EBMT 2024

2. Weide R, Feiten S, Kojouharoff G, Otremba B, Linde H, Lorentz C, Hensel M, Schnell R, Schmidt B, Lipke J, Knoblich J, Verpoort K, Köhler A, Mohm J, Müller L, Dörfel S, Schmalfeld M, Vehling-Kaiser U, Rothe A, Steinmetz HT, Karcher A, Ehscheid P, **Chemnitz JM**, Lutz C. Waldenström´s Makroglobulinemia: Routine Care in Germany 2020 – 2021.
DGHO 2023

3. Ruhnke L, Bill M, Zukunft S, Schäfer S, Eckardt JN, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf T, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, **Niemann D**, Seggewiß-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm A, Altmann H, Middeke JM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Validation of the revised 2022 european leukemianet (ELN) risk stratifikation in adult patients (PTS) with acute myeloid leucemia (AML)
EHA 2023
4. Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Ráčil Z, Schäfer-Eckart K, Sauer T, Neubauer A, Baldus CD, Mertová J, Jost E, **Niemann D**, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Serve H, Ehninger G, Mayer J, and Bornhäuser M. Remission and survival after single versus double induction with 7+3 containing 60 versus 90 mg daunorubicin for newly diagnosed acute myeloid leukemia: results from the randomized controlled SAL-DaunoDouble trial
ASH 2022 (oral presentation)
5. Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Schäfer-Eckart K, Steffen B, Krause SW, Schliemann C, Kaufmann M, Haenel M, Jost E, Crysandt M, Fransecky L, Einsele H, Kraus S, **Niemann D**, Neubauer A, Seggewiss-Bernhardt R, Scholl S, Klein S, Schmid C, Schaich M, Platzbecker U, Baldus CD, Bornhaeuser M, Serve H, Röllig C, Kramer M, Katelari E, Janssen M, Pabst C, Luft T, Dreger P, Müller-Tidow C, Sauer T. **Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis**
ASH 2022
6. Hamacher R, Liu X, Schuler MK, Hentschel L, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Kunitz A, Grünwald V. A post hoc analysis of the EPAZ trial: the role of geriatric variables in elderly soft tissue sarcoma (STS) patients on toxicity and outcome.
DKK 2022
7. Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt C, Aguiar E, Schäfer-Eckart K, Miguel Bergua J, Steffen B, Bernal T, Krause SW, Rianza R, Schliemann C, Kaufmann M, Hänel M, Jost E, Crysandt M, Fransecky L, Kraus S, Einsele H, **Niemann D**, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein S, Schmid C, Schaich M, Schmidt-Hieber M, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Montesinos P, Röllig C, Schlenk RF. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
ASH 2021
8. Unglaub JM, Schlenk RF, Hanoun M, Reinhardt C, Middeke M, Schäfer-Eckart K, Steffen B, Krause SW, Schliemann C, Kaufmann M, Hänel M, Jost E, Crysandt M,

Fransecky L, Kraus S, Einsele H, **Niemann D**, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein S, Schmid C, Schaich M, Schmidt-Hieber M, Platzbecker U, Baldus CD, Bornhäuser M, Serve H, Röllig C, Kramer M, Janssen M, Pabst C, Luft T, Dreger P, Müller-Tidow C and Sauer T for the Study Alliance Leukemia (SAL). Venetoclax-Azacitidine as salvage therapy and bridge to allogeneic cell transplantation in relapse/refractory AML compared to historical data of the SAL registry study
ASH 2021

9. Hanoun M, Ruhnke L, Kramer M, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Kaufmann M, Hänel M, Jost E, Brümmendorf T, Fransecky L, Kraus S, Einsele H, **Niemann D**, Neubauer A, Kullmer J, Seggewiß-Bernhardt R, Görner M, Held G, Kaiser U, Scholl S, Reinhardt C, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C for the Study Alliance Leukemia (SAL). Higher dose cytarabine in consolidation therapy for AML patients under 65 years does not implicate survival benefit
ASH 2021
10. Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch JH, Krause S, Sauer T, Hanoun M, Reinhardt C, Kraus S, Kaufmann M, Hänel M, Fransecky L, Burchert A, Neubauer A, Crysandt M, Jost E, **Niemann D**, Schäfer-Eckart K, Held G, Kaiser U, Wass M, Schaich M, Müller-Tidow C, Platzbecker U, Baldus CD, Bornhäuser M, Röllig C, Serve H, Steffen B for the Study Alliance Leukemia (SAL). Impact of body mass index on patient outcome in acute myeloid leukemia patients receiving intensive induction therapy: a real-world registry experience.
ASH 2021
11. Hamacher R, Liu X, Schuler M, Hentschel L, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Kunitz A, Viktor Grünwald. A post hoc analysis of the EPAZ trial: the role of geriatric variables in elderly soft tissue sarcoma (STS) patients on toxicity.
CTOS 2021
12. Hamacher R, Liu X, Schuler M, Hentschel L, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Richter S, Egerer G, Ivanyi P, Kunitz A, Viktor Grünwald. A post-hoc analysis of the EPAZ trial: the predictive role of geriatric variables in elderly soft tissue sarcoma (STS) patients.
ESMO 2021
13. Röllig C, Hanoun M, Steffen B, ... **Niemann D**, ... Thiede C. Prevalence and prognostic impact of IDH mutations in the real-world setting: Results from the prospective IDH screening cohort of the SAL AML registry.
EHA 2021
14. Liebers N, ...**Chemnitz J**,Dietrich S. Polatuzumab vedotin in relapsed and refractory (r/r) large B-cell lymphoma (LBCL): Real-world data of the German national compassionate use program (CUP)
ASH 2020

15. Röllig C, **Niemann D**, Bornhäuser M. Remission and survival after single versus double Induction with 7+3 for newly diagnosed acute myeloid leukemia: results from the planned interim analysis of randomized controlled SAL-DaunoDouble trial
ASH 2020
16. Rösch R, Kubin T, Südhoff T, Hartmann F, Wendtner C, Hebart H, Schaich M, Seggewiss-Bernhardt R, Späth-Schwalbe E, Kaiser U, Kapp M, Graeven U, Naumann R, **Chemnitz J**, Baesecke J, Kiani A. Charakteristika und klinischer Verlauf von Tumorpatienten mit SARS-CoV-2-Infektion in Deutschland: Erste Ergebnisse des Coronavirus-Tumorregisters (CoRe) der Arbeitsgemeinschaft Deutscher Hämatologen und Onkologen im Krankenhaus (ADHOK)
DGHO 2020
17. Röllig C, Steffen B, Herbst R, ... **Niemann D** ..., Bornhäuser M. Remission and Survival after 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia: Results from the randomized controlled SAL-DaunoDouble trial.
EHA 2020
18. **Clemens M**, Niemann D, von Witzendorff S, Stöcklein S, Kröber S, Said S, Felber S, **Chemnitz JM**. Mykobacterium avium-Infektion bei einem Patienten mit T-Prolymphozytenleukämie unter Alemtuzumab-Therapie.
SPIG 2019
19. Hentschel L, Richter S, Kopp H-G, Kaspar B, Kunitz A, Grünwald V, Kessler T, **Chemnitz JM**, Pelzer U, Schuler U, Freitag J, Schilling A, Hornemann B, Arndt K, Ehninger G, Bornhäuser M, Schuler MK. Supportive intervention to improve Quality of Life (QoL) for patients with soft tissue sarcoma (STS) undergoing palliative treatment: a multicenter , cluster-randomized, controlled trial within the German Interdisciplinary Sarcoma Group.
DGHO 2019
20. Grünwald V, Länger F, Kunitz A, Schuler M, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Kneba M, Egerer G, Zimmermann S, Ivanyi P, Karch A. Soft tissue sarcomas express a distinct mRNA immune profile
ESMO 2019
21. Pflug N, Chakupurakal G, Theurich S, Holtick U, Leitzke S, **Chemnitz J**, Scheid C, Hallek M, von Bergwelt-Baildon, M. Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience.
DKK 2018
22. Grünwald V, Kunitz A, Schuler MK, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner LH, **Chemnitz JM**, Crysandt MM, Stein A, Steffen B, Egerer G, Zimmermann S, Karch A. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).
ASCO 2018

23. Hartmann JT, Kopp HG, Gruenwald V, Piperno-Neumann S, Kunitz A, Hofheinz R, Mueller L, Geissler M, Horger M, Fix P, **Chemnitz JM**, Eckert R, Hann von Weyhern C, Bauer S, Mayer F. Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.
ASCO 2018

24. Hentschel L, Richter S, Kopp HG, Kasper B, Kunitz A, Grünwald V, Kessler T, **Chemnitz JM**, Pelzer U, Schuler US, Freitag J, Schilling A, Hornemann B, Arndt K, Ehninger G, Bornhäuser M, Schuler M. Quality of Life in patients with soft tissue sarcoma undergoing palliative treatment – A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12).
ESMO 2018

25. Grünwald V, Schuler M, Schöffski P, Kopp HG, Bauer S, Kasper B, Lindner L, **Chemnitz JM**, Crysandt M, Stein A, Steffen B, Richter S, Kneba M, Egerer G, Zimmermann S, Karch A, Kunitz A. Health-related Quality of Life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line.
ESMO 2018

26. Rollig C, Steffen B, Herbst, R... **Niemann D**, ... Ehninger G. Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia: Results from the SAL-DaunoDouble trial.
DGHO 2018

27. Platzbecker U, Lengfelder E, Schafer-Eckart K, ..., **Niemann D**, ... Paschka P. Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry.
ASH 2017

28. Ram R, Scheid C, Amit O, **Chemnitz JM**, Moshe Y, Hallek M, Wolf D, Avivi I and Holtick U. Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience. Blood 2017 130:4579
ASH 2017

Buchbeiträge

1. **Chemnitz J**. Immunthrombozytopenie
Referenzwerk Hämatologie, Springer Verlag (2018)

2. **Chemnitz J**. Morphologie der Blutzellen (Erythrozyten)
Barbara J., Bain and Karl-Anton Kreuzer (Ed.). 2017. Das Blutbild. Diagnostische Methoden und klinische Interpretation. Berlin, Boston: De Gruyter.
ISBN 978-3-11-044215-1